GlobeNewswire

Elemica Wins Three Prestigious Supply Chain Awards This Month

Share

Elemica Awarded for Creating Supply Chain Excellence With Next-Gen Technologies

ATLANTA, June 25, 2019 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, announces that the company has been honored with two top supply chain awards, and Gary Neights, Senior Director of Product Management at Elemica, was named a Top 50 Tech Visionary.

“The industry is recognizing Elemica and its people for their innovative solutions and robust platform that produces exceptional business results for clients,” said David Cahn, Director of Global Marketing at Elemica. “Elemica has been instrumental this year in helping numerous global businesses move forward on their digital transformations, resulting in improved visibility, greater efficiencies, and better bottom line results.”

Supply & Demand Chain Executive has selected Elemica as a recipient of the SDCE 100 Award for the 7th consecutive year. Food Logistics magazine has bestowed Elemica with a Top Green Supply Chain Providers Award for the 5th consecutive year. Finally, Gary Neights has been selected as a Top 50 Tech Visionary at the Intercon Conference in Las Vegas, where he spoke on Artificial Intelligence and Machine Learning.

The SDCE 100 is an annual list of 100 great supply chain projects. Elemica was instrumental in the success of a global supply chain merger between two chemical giants. Through Elemica’s Digital Supply Network, the merged business is able to conduct frictionless business processes with trading partners worldwide.

The Food Logistics Top Green Supply Chain Providers award recognizes companies whose products, services, or exemplary leadership is enhancing sustainability within the food and beverage industry. Elemica helps food and beverage ingredient customers improve and achieve their measurable sustainability goals through the automation of manual processes, reducing their usage of paper, which saves trees and other resources.

Gary Neights, Senior Director of Product Management at Elemica, is one of the top thought leaders in the industry in next-gen technologies like Artificial Intelligence, Machine Learning, Data Analytics, and more. Gary has been selected as a Top 50 Tech Visionary at the Intercon Conference, which brings together the best minds in technology to share best practices and innovative thinking. Gary was chosen for this distinguished award for continuing to bring innovations to light that leverage Elemica’s next-generation platforms. These developments include robotic process automation (RPA), “no-configuration needed” analytics, and an inter-company data management product that offers clients the ability to save millions of dollars per year by eliminating ERP data quality issues.  

“These recent recognitions solidify Elemica as a respected leader in supply chain digital transformations for process manufacturers,” adds Cahn. “Our clients are connecting, automating, anticipating and transforming to digital supply chains that drive lasting operational excellence and a competitive edge.”

About Elemica
Elemica is the leading Digital Supply Network for the process manufacturing industries. Elemica accelerates digital transformation by connecting, automating, anticipating, and then transforming inter-business supply chain processes for the products they buy, sell, move, and comply. Launched in 2000, customers process over $500B in commerce annually on the network. For more information, visit www.elemica.com.

For More Information, Contact:
Becky Boyd
MediaFirst
(770) 642-2080 x 214
becky@mediafirst.net

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Scanship Holding ASA : Invitation to 3Q2019 Trading update on Tuesday 22 October14.10.2019 21:52:00 CESTPress release

Welcome to Scanship Holding ASA's 3Q2019 Trading update at hrs. 12.00 on Tuesday 22 October in Oslo. With the recent acquisition of ETIA, Scanship has significantly broadened and expanded its adressable market, and the presentation will include more insight to forward growth strategies within the various landbased markets. Special attention will be given on Scanship's value proposition for the European biogas market and within chemical recycling of plastic waste. The presentation will be held at MESH in Tordenskioldsgate 3, and a light lunch will be served. Please notify Scanship by e-mail to attend: erik.magelssen@scanship.no, or cell + 47 928 88 728 Venue: MESH, the Lounge, Tordenskiolds gate 3, 0160 Oslo For further queries, please contact: Henrik Badin - CEO Scanship Holding ASA Tel: +47 90 78 98 25 Email: henrik.badin@scanship.no ABOUT SCANSHIP HOLDING ASA Scanship delivers world leading solutions for cleaner oceans in the Cruise and Aquaculture industries. Scanship provides advan

Notice of extraordinary general meeting in Oasmia Pharmaceutical AB14.10.2019 20:48:00 CESTPress release

The shareholders of Oasmia Pharmaceutical AB (the “Company”) are hereby given notice of the extraordinary general meeting on Wednesday 6 November 2019, at 14:00 CET, at the offices of the Company, Vallongatan 1, 752 28 Uppsala. The registration opens at 13:30 CET. NOTICE OF ATTENDANCE Shareholders who wish to participate in the general meeting must be recorded in the share register kept by Euroclear Sweden AB as of Wednesday 30 October 2019 and give notice of intent to participate to the Company no later than on Wednesday 30 October 2019, either by letter to Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, Sweden, by facsimile: +46 (0)18-51 08 73 or by e-mail: info@oasmia.com, and specify the number of advisors (maximum two). If shareholder’s attendance and right at the meeting will be exercised by proxy, we would be grateful if such is provided in connection with the notification of attendance. A proxy form is available to shareholders upon request and is avaliable at the Comp

Kallelse till extra bolagsstämma i Oasmia Pharmaceutical AB14.10.2019 20:48:00 CESTPressemelding

Aktieägarna i Oasmia Pharmaceutical AB (”Bolaget”) kallas härmed till extra bolags­stämma onsdagen den 6 november 2019 kl. 14:00, i Bolagets lokaler, Vallongatan 1, 752 28 Uppsala. Inregistrering påbörjas kl. 13:30. ANMÄLAN Aktieägare som önskar delta vid bolagsstämman skall dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 30 oktober 2019, dels anmäla sitt deltagande till Bolaget senast onsdagen den 30 oktober 2019 under adress Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, per fax: 018-51 08 73 eller via e-post: info@oasmia.com, varvid antalet biträden skall anges (högst två). Om deltagande skall ske med stöd av fullmakt är vi tacksamma om sådan ges in redan i samband med anmälan. Fullmakten får inte vara äldre än ett år gammal, dock att fullmakten får vara äldre än ett år om det framgår att den är giltig för en längre period, längst fem år. Fullmaktsformulär tillhandahålls aktieägare på begäran och finns tillgängligt hos Bolaget och på Bolagets we

The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million14.10.2019 20:46:00 CESTPress release

The Board of Directors in Oasmia Pharmaceutical AB (”Oasmia” or the ”Company”) today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the extra general meeting resolves to authorise the Board of Directors to carry out a rights issue of approximately SEK 400 million (the “Rights Issue”). The proceeds from the Rights Issue will primarily be used to finance and accelerate the commercialization of Apealea® and capture new business opportunities based on the Company's proprietary XR17 platform. Moreover, Oasmia intends to create a stable financial position enabling a solid platform for growth. The Company’s major shareholder Per Arwidsson through Arwidsro Investment AB and related parties (“Arwidsro”) has undertaken to subscribe for its pro-rata share in the Rights Issue, corresponding to approximately SEK 100 million or 25 percent. Oasmia has also received a financing commitment from Arwidsro enabling Oasmia to repay the convertible loan on 31 October

Styrelsen i Oasmia föreslår en företrädesemission om cirka 400 MSEK14.10.2019 20:46:00 CESTPressemelding

Styrelsen i Oasmia Pharmaceutical AB (”Oasmia” eller ”Bolaget”) offentliggör idag kallelse till extra bolagsstämma den 6 november 2019. Bolagsstämman föreslås besluta att bemyndiga styrelsen att genomföra en företrädesemission om cirka 400 MSEK (”Företrädesemissionen”). Likviden från Företrädesemissionen ska huvudsakligen användas för att finansiera och accelerera kommersialiseringen av Apealea® samt tillvarata nya affärsmöjligheter baserade på Bolagets egenutvecklade XR17-plattform. Därutöver avser Oasmia att skapa en stabil finansiell position för att möjliggöra framtida tillväxt. Bolagets största aktieägare Per Arwidsson via Arwidsro Investment AB och närstående (”Arwidsro”) har åtagit sig att teckna sig för sin pro rata-andel i Företrädesemissionen, motsvarande cirka 100 MSEK eller 25 procent. Oasmia har också fått ett finansieringsåtagande från Arwidsro som möjliggör för Oasmia att återbetala det utestående konvertibellånet den 31 oktober 2019. Sammanfattning Styrelsen offentliggö

Arion Bank: Discontinued operations and assets held for sale have negative impact on Q3 2019 financial results14.10.2019 20:29:00 CESTPress release

Discontinued operations and assets held for sale will have a negative impact of approximately ISK 3 billion after tax on Arion Bank’s Q3 2019 financial results, compared with a loss of ISK 715 million in Q2 2019. Discontinued operations held for sale refer to assets or companies which the Bank intends to sell in the next few months and are placed below net earnings from continuing operations in the income statement. Increased losses in the quarter are attributable to three factors: As a result of the challenging markets, including the low global price of silicon, Arion Bank is making an impairment of ISK 1.5 billion in respect of assets owned by Stakksberg. Stakksberg is a holding company for the silicon plant at Helguvík which is in the process of being sold. Preparations to sell the plant have been ongoing and an environmental impact assessment has been commissioned and new agreements with energy companies negotiated. Due to difficult conditions in the travel industry, Arion Bank is